Published: September 26, 2019

Introduction {#sec1}
============

Uterine endometrial cancer is one of the most common gynecological malignancies ([@bib29]). Despite macroscopic complete surgical resection of the cancerous tumor plus adjuvant chemotherapy, high-grade endometrial cancer cells tend to form recurrent metastatic tumors ([@bib32], [@bib43]). Moreover, the 5-year overall survival rate for advanced-stage cancer with distance metastasis is no more than ∼25% ([@bib2]). Currently combination drug therapies with taxanes (paclitaxel or docetaxel) and platinum analogs (carboplatin or cisplatin) are used as a first-line chemotherapy for endometrial cancer ([@bib4], [@bib32]); however, the appropriate chemotherapy regimen for high-risk disease is still controversial ([@bib6], [@bib29]). Thus, establishing a better chemotherapeutic strategy is essential for the treatment of advanced endometrial cancer.

Cancer stem cells (CSCs) are a small fraction of cancer cells with central roles in cancer propagation and proliferation among heterogeneous tumors ([@bib28]) and are thought to contribute to metastatic spread and resistance to chemotherapy and radiotherapy. Previous research has shown that a small population of freshly isolated cells from clinical endometrial cancer tissues has the capacity for clonogenicity *in vitro* and tumorigenicity *in vivo* ([@bib15]), and that transiently cultured endometrial cells are resistant to cisplatin- and paclitaxel-induced cytotoxicity ([@bib40]), suggesting the presence of CSC-like cells in endometrial cancers. However, the detailed biology of endometrial CSCs in clinical specimens has not been elucidated, potentially as a result of difficulties in the stable *in vitro* cultivation of endometrial CSCs isolated from clinical tumors.

Cells with characteristics of CSCs can be expanded *in vitro* under floating conditions in a unique three-dimensional format called tumor-derived spheroids or tumor spheres ([@bib35], [@bib48]); the spheroid cultivation system may facilitate identification of the biological characteristics of CSCs. Hence, this cultivation method has been established in several types of malignant tumors ([@bib8], [@bib26], [@bib39], [@bib44]). Previously, we generated stable cancer spheroid cells with CSC characteristics from clinical colorectal and ovarian cancer specimens ([@bib33], [@bib16]).

In this study, we aimed to develop a stable culture method for CSC spheroids from clinical endometrial cancer specimens. Our results demonstrated that aldehyde dehydrogenase (ALDH), via enhanced glycolysis through glucose transporter 1 (GLUT1) upregulation, plays an important role in the maintenance of endometrial CSCs. Further investigation revealed the synergistic effects of inhibition of ALDH activity or GLUT1 with taxane treatment on cell proliferation *in vitro* and tumorigenesis *in vivo*.

Results {#sec2}
=======

Human Uterine Endometrial Cancer Spheroid Cells Exhibit CSC-like Characteristics {#sec2.1}
--------------------------------------------------------------------------------

To develop new therapeutic strategies for refractory endometrial cancer, *in vitro* three-dimensional culture systems from human clinical specimens may provide a useful platform. Hence, we attempted to establish a cultivation method for spheroid cells from human uterine endometrial cancer tumors. Spheroid cells from 8 of 19 high-grade carcinoma samples (42%), and one case of grade 2 endometrioid carcinoma could be expanded under the spheroid culture conditions ([Table S1](#mmc2){ref-type="supplementary-material"}; [Figure 1](#fig1){ref-type="fig"}A). Interestingly, the established endometrial cancer spheroid cells were capable of proliferating under floating conditions in the absence of ROCK inhibitors, which were required for proliferation and maintenance of ovarian and colorectal cancer spheroid cells ([@bib16], [@bib33]).Figure 1Spheroid Cells Derived from Human Endometrial Cancer with High ALDH Activity Shows CSC Characteristics and Genetic Background Similar to that of the Primary Tumor(A) H&E staining of the primary tumor (left), bright-phase image of the indicated spheroids (center left), H&E staining of xenograft tumors (center right), bright-phase image of cells grown under differentiation conditions (right). Scale bars, 100 μm.(B) Targeted sequencing analyses of the primary tumor, spheroid cells, and spheroid-derived xenograft tumors.(C) Western blot analyses of the spheroid cells and differentiated cells shown in (A).(D) FACS analyses of ALDH activity after ALDEFLUOR staining. Left gated population, ALDH-low cells; right gated population, ALDH-high cells.(E) Bright-phase images of spheroid formation (7 days after *in vitro* cultivation). Scale bars, 100 μm.(F) Time course analyses of cell growth in ALDH-high and ALDH-low cells after sorting. n = 4 independent experiments, p \< 0.001, Student\'s t tests.(G) Western blot analyses of ALDH-high and ALDH-low cells after sorting.(H) Gene set enrichment analyses of gene expression profiles between ALDH-high and ALDH-low cells.(I) Time course of ALDH activity *in vitro* after ALDEFLUOR sorting.(J) Volume (mean ± SEM) of xenograft tumors from 1 × 10^5^ ALDH-low and ALDH-high cells. n = 5 independent experiments, p = 0.002, Student\'s t tests.(K) Image of mice on day 33. ALDH-low cells were injected on the left side, and ALDH-high cells were injected on the right side.(L) H&E staining and immunostaining of xenograft tumors derived from ALDH-high and ALDH-low cells, 33 days after transplantation. Scale bars, 100 μm.(M) Limiting dilution analysis of ALDH-high cells and ALDH-low cells *in vivo* on day 23 after subcutaneous injection. p \< 0.01.(N) ALDH activity after ALDEFLUOR staining in cancer cells from ALDH-high and ALDH-low xenograft tumors. Experiments in (D to G) and (I to N) were performed with EMN24 cells.^∗∗^ p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

To evaluate the tumorigenicity of these spheroid cells, cells were injected into immunodeficient NOG mice. The generated xenograft tumors were histologically similar to the original human endometrial tumors ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A). Immunostaining patterns for PAX8, cytokeratin 7, and p53 were similar between primary and xenograft tumors ([Figure S1](#mmc1){ref-type="supplementary-material"}B). To determine whether spheroid cells and primary tumors were genetically identical, targeted sequencing analysis was performed for 114 cancer-related genes ([Table S2](#mmc2){ref-type="supplementary-material"}). Overall the mutational profile of spheroid cells was identical to that of the original tumor except some mutations observed only in spheroids ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}C). The mutation profiles of spheroids and xenograft are identical, indicating that xenograft formation did not significantly promote additional oncogenic mutations. Most shared mutations were previously reported as common genomic alterations in endometrial cancer tissues, i.e., *PTEN*, *PIK3CA*, *ARID1A*, and *TP53* ([@bib46], [@bib45]).

ALDH Activity Is Related to the CSC Characteristics of Endometrial Cancer Spheroid Cells {#sec2.2}
----------------------------------------------------------------------------------------

Next, we examined the CSC characteristics of these established spheroids. Expression levels of stemness-related markers, including Nanog, c-myc, and ALDH1A1, were higher in the spheroid cells than in differentiated cells ([Figures 1](#fig1){ref-type="fig"}A and 1C). In accordance with elevated levels of ALDH1A1, fluorescence-assisted cell sorting (FACS)-sorted spheroid cells with high ALDH activity (ALDH-high cells) could form and expand spheroids more rapidly *in vitro* than cells with no or low ALDH activity (ALDH-low cells; [Figures 1](#fig1){ref-type="fig"}D--1F and [S1](#mmc1){ref-type="supplementary-material"}D--S1F). Western blot analysis showed that ALDH-high cells expressed higher levels of the stemness markers Oct-4, c-myc, and ALDH1A1 than ALDH-low cells ([Figures 1](#fig1){ref-type="fig"}G and [S1](#mmc1){ref-type="supplementary-material"}G). Moreover, gene set enrichment analysis (GSEA) demonstrated that ALDH-high cells preferentially expressed stem cell-related genes found in breast cancer (false discovery rate \[FDR\] q value \< 0.01, normalized enrichment score \[NES\] 2.16) ([@bib36]) and embryonic stem cells (ESCs) (FDR q value \< 0.01, NES 2.02) ([@bib50]) ([Figure 1](#fig1){ref-type="fig"}H), which may reflect the activation of an ESC-like transcriptional program in endometrial cancer. Induction of stem cell-related genes was previously reported in other types of human cancers, including glioblastoma (grade 4), breast cancer, and lung cancer ([@bib3], [@bib50]). Although ALDH-high cells generated both ALDH-high and ALDH-low cells, ALDH-low cells propagated more slowly than ALDH-high cells and did not give rise to ALDH-high cells during *in vitro* cultivation ([Figure 1](#fig1){ref-type="fig"}I). These results indicated that ALDH-high cells had the CSC ability to self-renew and to differentiate into ALDH-low cells. In contrast, high expression levels of CD44 or CD133 were not associated with the capability to form spheres *in vitro* ([Figures S1](#mmc1){ref-type="supplementary-material"}H--S1K).

Next, we explored the tumorigenic ability of ALDH-high cells *in vivo.* The FACS-sorted ALDH-high cells generated xenograft tumors more aggressively than ALDH-low cells ([Figures 1](#fig1){ref-type="fig"}J--1L and [S1](#mmc1){ref-type="supplementary-material"}L). *In vivo* serial dilution spheroid cell assays showed that the tumorigenic ability of ALDH-high cells was higher than that of ALDH-low cells (p \< 0.0001; [Figure 1](#fig1){ref-type="fig"}M). ALDH activity assays and immunohistochemical analyses showed that the xenograft tumors from ALDH-high cells contained both ALDH-high cells and ALDH-low cells, whereas tumors from ALDH-low cells contained only ALDH-low cells ([Figures 1](#fig1){ref-type="fig"}L and 1N); these *in vivo* results were consistent with the *in vitro* results ([Figure 1](#fig1){ref-type="fig"}I). Immunohistochemical analyses also showed that xenograft tumors from ALDH-high cells contained more Ki67-positive cells than tumors from ALDH-low cells ([Figure 1](#fig1){ref-type="fig"}L). These results indicated that ALDH-low cells were derived from CSC-like ALDH-high cells.

Inhibition of ALDH Activity Reduces the Propagation of Endometrial Cancer Spheroid Cells {#sec2.3}
----------------------------------------------------------------------------------------

Next, we attempted to determine whether ALDH1A1 or other isoforms of ALDH were responsible for ALDH activity in the endometrial cancer spheroids. The ALDH family is composed of at least 19 functional isoforms with similar catalytic functions ([@bib47]). Although each of the established spheroid cells had different levels of ALDH activities, qRT-PCR analyses showed that only *ALDH1A1* mRNA expression was clearly correlated with ALDH activity (Spearman R value = 0.92, p \< 0.01; [Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A). The association between ALDH1A1 expression and ALDH activity was confirmed by western blotting ([Figure S2](#mmc1){ref-type="supplementary-material"}B) and by immunocytochemical analyses, which showed that most ALDH-high cells expressed detectable ALDH1A1 ([Figure 2](#fig2){ref-type="fig"}B), although some spheroid cells also expressed higher levels of other ALDH isoforms ([Figure S2](#mmc1){ref-type="supplementary-material"}B).Figure 2Inhibition of ALDH Activity Blocks the Formation and Proliferation of Spheroid Cells (EMN24 cells)(A) Correlation between ALDH activity and *ALDH1A1* mRNA levels on culture day 10.(B) Immunofluorescence staining with anti-ALDH1A1 antibody and DAPI in ALDH-high and ALDH-low cells after sorting. Scale bars, 20 μm.(C) Western blot analyses of spheroids cells after disulfiram treatment for 24 h.(D) FACS analyses of ALDH activity in the presence or absence of disulfiram (24 h after treatment).(E) Time course of cell growth in spheroid cells treated with the indicated amounts of disulfiram. n = 4 independent experiments, p \< 0.001, Student\'s t test.(F) Bright-phase images of spheroids (7 days after disulfiram treatment). Scale bars, 100 μm.(G) Responses of ALDH-high and ALDH-low cells to different concentrations of disulfiram after treatment for 7 days. n = 4 independent experiments, p \< 0.001, Student\'s t test.(H) Tumor volumes (mean ± SEM) of xenograft tumors from 1 × 10^5^ spheroid cells subcutaneously injected. Disulfiram (40 mg/kg) was intraperitoneally injected into mice in the disulfiram-treatment group, and vehicle (DMSO) was intraperitoneally injected into mice in the control group. n = 12 independent experiments, p \< 0.001, Student\'s t test.(I) Images of whole resected tumor xenografts excised on day 17. Scale bar, 10 mm.(J) ALDH activity of the cancer cells derived from xenograft tumors.(K) H&E staining and immunostaining of xenograft tumors, 17 days after transplantation. Scale bars, 100 μm.(L) Western blot analyses after infection with the indicated lentiviruses.(M) ALDH activity in the infected cells after ALDEFLUOR staining.(N) Time course of proliferation of infected cells. n = 4 independent experiments, p \< 0.01, Student\'s t test.(O) Bright-phase images of the infected cells on day 7. Scale bars, 100 μm.^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Consistent with ALDH1A1 expression in spheroids ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}B), xenograft tumors derived from EMN8 and EMN102 cells showed strong staining of ALDH1A1, whereas those from EMN103 cells showed weak expression of ALDH1A1 ([Figure S2](#mmc1){ref-type="supplementary-material"}C).

We then examined differences in function after treatment with the pan-ALDH-specific inhibitor disulfiram. Although exposure to disulfiram did not significantly change ALDH1A1 expression (EMN24 cells, [Figure 2](#fig2){ref-type="fig"}C), disulfiram treatment suppressed ALDH activity ([Figure 2](#fig2){ref-type="fig"}D) and spheroid propagation ([Figures 2](#fig2){ref-type="fig"}E and 2F). Other spheroid cells (i.e., EMN81 cells) were more sensitive to disulfiram than EMN24 spheroid cells ([Figures S2](#mmc1){ref-type="supplementary-material"}D--S2F), and the surviving cells retained reduced levels of ALDH1A1 expression after treatment ([Figure S2](#mmc1){ref-type="supplementary-material"}G). ALDH-high cells were more sensitive to disulfiram than ALDH-low cells ([Figures 2](#fig2){ref-type="fig"}G and [S2](#mmc1){ref-type="supplementary-material"}H).

To further confirm the inhibitory effects of ALDH inhibition, we used three other ALDH inhibitors, diethylaminobenzaldehyde (DEAB), CM037, and NCT501 (a selective inhibitor of ALDH1A1). Again, these ALDH inhibitors caused inhibition of ALDH activity ([Figure S2](#mmc1){ref-type="supplementary-material"}I), reduction of spheroid cells ([Figure S2](#mmc1){ref-type="supplementary-material"}J), and preferential cell death in ALDH-high cells ([Figures S2](#mmc1){ref-type="supplementary-material"}K and S2L). Collectively, these data indicated that ALDH inhibition blocked spheroid cell propagation and spheroid formation via preferential targeting of ALDH-high cells.

Based on the effects of ALDH inhibitors on *in vitro* spheroid cells, we attempted to examine the effects of ALDH inhibitor treatment on tumor formation *in vivo*. Because disulfiram has been used in the preclinical and clinical settings ([@bib16], [@bib31], [@bib41], [@bib52], [@bib53]), we chose disulfiram to investigate the inhibitory effects *in vivo*. Disulfiram treatment suppressed tumorigenesis in spheroid cells *in vivo* ([Figures 2](#fig2){ref-type="fig"}H and 2I), markedly reduced a fraction of ALDH-high cells in the tumor ([Figure 2](#fig2){ref-type="fig"}J), and caused decreased levels of Ki-67 staining, not ALDH1A1 staining ([Figure 2](#fig2){ref-type="fig"}K). Thus, inhibition of ALDH activity by disulfiram treatment inhibited spheroid-derived tumor growth *in vivo*.

Next, we examined the functional effects of ALDH1A1 on cancer stemness, proliferation, and ALDH activity. Inhibition of ALDH1A1 expression by shRNA lentiviral transfer caused reduction of the stemness-related markers c-myc and Oct4 ([Figures 2](#fig2){ref-type="fig"}L and [S2](#mmc1){ref-type="supplementary-material"}M) and ALDH activity ([Figures 2](#fig2){ref-type="fig"}M and [S2](#mmc1){ref-type="supplementary-material"}N). In addition, ALDH1A1 inhibition blocked spheroid formation and propagation *in vitro* ([Figures 2](#fig2){ref-type="fig"}N, 2O, [S2](#mmc1){ref-type="supplementary-material"}O, and S2P).

Exogenous ALDH Expression Enhances the Stemness Features of Endometrial Cancer {#sec2.4}
------------------------------------------------------------------------------

We next examined whether exogenous ALDH1A1 overexpression enhanced the proliferation of endometrial cancer spheroid cells. Introduction of ALDH1A1 via lentivirus-mediated gene transfer into EMN24 cells augmented ALDH activity and expression of stemness-related markers ([Figures 3](#fig3){ref-type="fig"}A and 3B). Although ALDH1A1 expression caused a modest increase in the proliferation rate of the spheroids ([Figures 3](#fig3){ref-type="fig"}C and 3D), ALDH1A1 expression also resulted in the formation of the transplanted tumors that were four times larger than those formed after transplantation of control cells ([Figure 3](#fig3){ref-type="fig"}E). The xenograft tumors generated from the ALDH1A1-introduced spheroid cells contained more Ki67-positive cells than the control of xenograft tumors ([Figure 3](#fig3){ref-type="fig"}F). EMN21 cells, which showed the lowest ALDH activity among the established endometrial spheroid cells ([Figure 2](#fig2){ref-type="fig"}A), also propagated rapidly *in vitro* after the introduction of exogenous ALDH1A1 ([Figures S2](#mmc1){ref-type="supplementary-material"}Q--S2T). Collectively, our data indicated that ALDH activity, which was mainly attributed to ALDH1A1 expression, played an essential role in the survival and propagation of endometrial CSCs.Figure 3Exogenous ALDH1A1 Enhances the Formation and Proliferation of Spheroids and Tumorigenicity (EMN24 Cells)(A) Western blot analyses of spheroid cells after infection with the indicated lentiviruses.(B) ALDH activity in the infected cells after ALDEFLUOR staining.(C) Time course of proliferation of infected cells. n = 4 independent experiments, p \< 0.01, Student\'s t test.(D) Bright-phase images of the infected cells. Scale bars, 100 μm.(E) Volumes (mean ± SEM) of xenograft tumors from 1 × 10^5^ infected cells. n = 6 independent experiments, p \< 0.01, Student\'s t tests. Images of whole resected tumor xenograft tumors excised on day 25 (bottom). Scale bar, 10 mm.(F) H&E staining and immunostaining of xenograft tumors, 25 days after transplantation. Scale bars, 100 μm.^∗∗^p \< 0.01. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Spheroid Cells with ALDH Activity Are less Sensitive to Paclitaxel {#sec2.5}
------------------------------------------------------------------

Cancer stem-like cells have been reported to be responsible for drug resistance in many cancers ([@bib11], [@bib13]). To evaluate the drug sensitivity of cancer stem-like cells in our endometrial cancer spheroid cells, we examined the sensitivity of ALDH-high cells for paclitaxel or cisplatin, which have been used in the clinical setting as key drugs for the treatment of endometrial cancer ([@bib32]). Interestingly, although there were no significant differences in the sensitivity of ALDH-high and ALDH-low cells to cisplatin, ALDH-high cells were more resistant to paclitaxel than ALDH-low cells ([Figures 4](#fig4){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A).Figure 4Combination Therapy with Paclitaxel and the ALDH Inhibitor Synergistically Inhibits Endometrial Cancer Cell Progression (EMN24 Cells)(A) Responses of ALDH-high and ALDH-low cells to different concentrations of cisplatin and paclitaxel after treatment for 7 days. n = 4 independent experiments, Student\'s t test.(B) FACS analyses of ALDH activity in ALDH-high cells in the presence or absence of paclitaxel or cisplatin after *in vitro* treatment for 7 days.(C) Western blot analyses of ALDH-high cells treated with paclitaxel for 7 days.(D) Correlation between ALDH activity and paclitaxel half-maximal inhibitory concentration (nM).(E) Bright-phase images of spheroids after *in vitro* paclitaxel and disulfiram treatment for 7 days. Scale bars, 100 μm.(F) Relative cell viability of spheroid cells after culture for 7 days with the indicated concentrations of ALDH inhibitor and paclitaxel. Synergistic interaction was assessed with Combenefit software. n = 4 independent experiments.(G) *In vitro* limiting dilution analysis over 14 days culture using spheroid cells exposed to 7 days treatment of disulfiram and/or paclitaxel *in vitro*.(H) Volume (mean ± SEM) of xenograft tumors from 1 × 10^5^ spheroid cells. Mice were separated into the vehicle (DMSO)-treated group, paclitaxel-treated group, and paclitaxel + disulfiram-treated group. n = 8 independent experiments, p \< 0.001, Student\'s t test.(I) Images of whole resected tumor xenografts excised on day 23. Scale bar, 10 mm.(J) ALDH activity in cancer cells derived from xenograft tumors.^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Given the relative resistance of ALDH-high cells against paclitaxel, we examined whether ALDH-high cells preferentially survived following paclitaxel treatment. Treatment of spheroids with paclitaxel, but not with cisplatin, caused the proportion of ALDH-high cells to increase ([Figures 4](#fig4){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}B). Consistent with the major role of ALDH1A1 in ALDH activity of spheroids, ALDH1A1 increased after exposure to paclitaxel ([Figures 4](#fig4){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}C). Furthermore, evaluation of the ALDH activity and half-maximal inhibitory concentration of paclitaxel of nine established endometrial cancer spheroids revealed strong correlations (Spearman R value = 0.87, p \< 0.01; [Figure 4](#fig4){ref-type="fig"}D). These results indicated that an ALDH-high cell population in endometrial spheroid cells was responsible for paclitaxel resistance in endometrial cancer.

Because of the relative resistance of ALDH-high cells to paclitaxel, we examined the synergistic effects of paclitaxel and an ALDH inhibitor. Disulfiram synergistically suppressed spheroid cell proliferation *in vitro* when used in combination with paclitaxel ([Figures 4](#fig4){ref-type="fig"}E--4G and [S3](#mmc1){ref-type="supplementary-material"}D--S3F). Similarly, the combination of paclitaxel and other ALDH inhibitors (DEAB, CM037, and NCT501) suppressed spheroid cell propagation to a greater extent than paclitaxel alone ([Figure S3](#mmc1){ref-type="supplementary-material"}G).

To determine the synergistic effects of paclitaxel and disulfiram *in vivo*, we treated spheroid cell-transplanted mice with paclitaxel with or without disulfiram. The sizes of tumors observed after combination therapy were approximately one-eighth of those after paclitaxel alone ([Figures 4](#fig4){ref-type="fig"}H and 4I). As expected, paclitaxel treatment led to an increase in the population of ALDH-high cells, which was suppressed by additional treatment with disulfiram ([Figure 4](#fig4){ref-type="fig"}J). Thus, combination therapy with paclitaxel and the ALDH inhibitor synergistically inhibited endometrial cancer cell progression in *in vivo* tumors as well as *in vitro* spheroids.

ALDH1A1 Expression Is Correlated with Poor Prognosis in Patients with Endometrial Cancer {#sec2.6}
----------------------------------------------------------------------------------------

To examine whether ALDH1A1 expression was associated with prognosis in clinical endometrial cancer, we determined the expression of ALDH1A1 in 258 clinical primary uterine endometrial endometrioid carcinoma tumor tissue samples by immunohistochemistry ([Figure 5](#fig5){ref-type="fig"}A). The clinicopathological characteristics are shown in [Table S3](#mmc2){ref-type="supplementary-material"}. Immunostaining demonstrated that ALDH1A1 was expressed in more than 40% of tumor samples in patients with advanced-stage disease (stages III and IV), but was expressed only in 10% of patients with early-stage disease (stages I and II; [Figure 5](#fig5){ref-type="fig"}B). In addition, significantly higher levels of ALDH1A1 were observed in patients with high-grade endometrioid cancer than in patients with low-grade cancer ([Figure 5](#fig5){ref-type="fig"}B). Moreover, a fraction of ALDH1A1-expressed cells was higher in clinical specimens from advanced-stage or high-grade cancer than from early-stage or low-grade cancer ([Figure 5](#fig5){ref-type="fig"}C). Kaplan-Meier survival analyses of 35 patients with advanced-stage cancer showed that high ALDH1A1 expression was correlated with survival rate ([Figure 5](#fig5){ref-type="fig"}D, p \< 0.01 for progression-free survival; [Figure 5](#fig5){ref-type="fig"}E, p = 0.015 for overall survival), consistent with previous reports ([@bib14], [@bib37]). Univariate and multivariate analyses revealed that positive ALDH1A1 staining was an independent prognostic factor of both progression-free and overall survival in patients with advanced-stage endometrial cancer ([Tables S4](#mmc2){ref-type="supplementary-material"} and [S5](#mmc2){ref-type="supplementary-material"}). These results indicated that ALDH1A1 expression was associated with pathological grade and poor prognosis.Figure 5ALDH1 Expression Is Associated with Advanced Clinical Stage, Poor Prognosis, and Paclitaxel Sensitivity in Human Endometrial Cancer(A) Representative immunostaining of ALDH1A1 (score 0--3). Scale bars, 100 μm.(B) Distribution of ALDH1A1 expression during different clinical stages in endometrial cancer, and distribution of ALDH1A1 expression in different histological grades of endometrial cancer (n = 258).(C) Percentage of ALDH1A1-expressed cancer cells in different clinical stage or histological grades of endometrial cancer (n = 258).(D and E) Kaplan-Meier analyses of progression-free survival (D) and overall survival (E) in patients with advanced-stage endometrial cancer. The patients were stratified into ALDH1A1-positive (red lines, n = 15) and ALDH1A1-negative (gray lines, n = 20) groups. Most of these patients were treated with taxane-containing chemotherapy as the first-line regimen.(F) Immunostaining for ALDH1A1 in uterine tumors before and after chemotherapy. Scale bars, 100 μm (left). ALDH1A1 immunostaining area in uterine tumors before and after chemotherapy (right). Cases of ALDH1A1 staining area expanded up to five times are indicated as straight lines (n = 6), and other cases are indicated as dotted lines (n = 4).See also [Table S3](#mmc2){ref-type="supplementary-material"}.

Furthermore, we compared the expression levels of ALDH1A1 by immunostaining of paired uterine endometrial tumor samples before and after taxane-containing chemotherapy. Immunostaining analysis showed that, in six of ten patient samples, the ALDH1A1 staining area expanded more than five times after chemotherapy compared with that in matched tumor samples before chemotherapy ([Figure 5](#fig5){ref-type="fig"}F), thus further supporting the proposed role of ALDH-positive cells in paclitaxel resistance.

Spheroid Cells with ALDH Activity Show Glycolytic Dependency {#sec2.7}
------------------------------------------------------------

Next, to gain an insight into mechanism by which ALDH function confers for the observed chemoresistance, we searched for biological pathways that were upregulated in cells with high levels of ALDH. GSEA showed the upregulation of glycolysis-related genes (hallmark of glycolysis) in the ALDH-high spheroid cells ([Figure 6](#fig6){ref-type="fig"}A). In fact, ALDH-high cells displayed higher levels of the extracellular acidification rate (ECAR) than ALDH-low cells ([Figures 6](#fig6){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}A) and the treatment with disulfiram reduced ECAR ([Figures 6](#fig6){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}B), indicating that glycolysis and glycolytic capacity were elevated in ALDH-high cells. In accordance with these results, glucose uptake, intracellular glucose, and lactate level were higher in ALDH-high cells than in ALDH-low cells ([Figures 6](#fig6){ref-type="fig"}D--6F and [S4](#mmc1){ref-type="supplementary-material"}C--S4E) and suppressed by disulfiram ([Figures 6](#fig6){ref-type="fig"}D--6F and [S4](#mmc1){ref-type="supplementary-material"}C--S4E). These data collectively indicate that spheroid cells with ALDH activity had increased glycolytic activity.Figure 6ALDH-High Endometrial Cancer Cells Depend on Glycolysis for Their Survival and Growth(A) Gene set enrichment analyses of gene expression profiles between ALDH-high and ALDH-low cells (Hallmark of glycolysis).(B and C) Time course of ECAR of spheroid cells with the indicated stimulation. The differences between ALDH-high and ALDH-low cells (B), and between ALDH-high cells with vehicle or disulfiram treatment (C). n = 4 independent experiments.(D--F) Relative glucose uptake (D), intracellular glucose (E), and lactate level (F) of ALDH-low cells, ALDH-high cells, and ALDH-high cells treated with disulfiram. n = 4 independent experiments, p \< 0.01, Student\'s t test.(G) Time course of the proliferation of ALDH-high and ALDH-low cells under no glucose culture condition. n = 4 independent experiments, Student\'s t test.(H) FACS analyses of ALDH activity in ALDH-high cells cultivated under normal or no glucose condition for 2 days.(I) Time course of the proliferation of ALDH-high and ALDH-low cells under 20μM 2-deoxy-D-glucose (2-DG) treatment. n = 4 independent experiments, Student\'s t test.^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

To examine whether reduced availability of glucose affects cell growth of ALDH-high cells, we cultivated ALDH-high and ALDH-low cells under glucose-free cultivation condition, and found that the reduced levels of glucose led to the relative suppression of cell growth in ALDH-high cells ([Figure 6](#fig6){ref-type="fig"}G) as well as the decrease of their proportion ([Figure 6](#fig6){ref-type="fig"}H). Similarly, 2-deoxy-D-glucose, an inhibitor of hexokinase, similarly suppressed cell growth of ALDH-high spheroid cells ([Figure 6](#fig6){ref-type="fig"}I). Thus, ALDH-high cells were more dependent on glycolytic function than ALDH-low cells for their survival and growth.

Glycolytic Suppression with GLUT1 Inhibition Suppressed Endometrial Cancer Stemness {#sec2.8}
-----------------------------------------------------------------------------------

Glucose transporters play an essential role in glucose influx, and 14 members of the glucose transporter (GLUT) family have been reported. Because some of the transporters are overexpressed or dysregulated in cancer cells ([@bib54]), we evaluated the differences in GLUT expression in ALDH-high and ALDH-low cells. Western blot analysis showed that GLUT1 was specifically expressed at higher levels in ALDH-high cells than in ALDH-low cells ([Figures 7](#fig7){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}F). ALDH1A1 was responsible for GLUT1 expression because inhibition of ALDH1A1 decreased the expression of GLUT1 and exogenous ALDH1A1 overexpression led to the increase of GLUT1 expression ([Figure 7](#fig7){ref-type="fig"}A).Figure 7Combination Therapy with Paclitaxel and the GLUT1 Inhibitor Synergistically Inhibits Endometrial Cancer Cell Progression (EMN24 Cells)(A and B) Western blot analyses of spheroid cells after indicated ALDH modification (A) and after GLUT1 inhibition (B).(C) Time course of the proliferation of the infected cells. n = 4 independent experiments, p \< 0.01, Student\'s t test.(D) Bright-phase images of the infected cells. Scale bars, 100 μm.(E) Glucose uptake of spheroid cells of the infected cells. n = 4 independent experiments, p \< 0.01, Student\'s t test.(F and G) Relative cell viability (F) and glucose uptake (G) of spheroid cells after culture for 7 days with the indicated concentration of BAY876. n = 4 independent experiments, p \< 0.01, Student\'s t test.(H) Western blot analyses of spheroid cells after exposure to the indicated concentration of BAY876.(I) Relative cell viability of spheroid cells after culture for 7 days with 2 nM paclitaxel. n = 4 independent experiments, p \< 0.01, Student\'s t test.(J) Relative cell viability of spheroid cells with the indicated concentrations of BAY876 and paclitaxel *in vitro*. Synergistic interaction was assessed with Combenefit software. n = 4 independent experiments.(K) Volume (mean ± SEM) of xenograft tumors from 1 × 10^5^ spheroid cells. Mice were separated into the vehicle (DMSO)-treated group, paclitaxel-treated group, BAY876-treated group, and paclitaxel + BAY876-treated group. n = 12 independent experiments, p \< 0.001, Student\'s t test.(L) Images of whole resected tumor xenografts excised on day 23. Scale bar, 10 mm.(M) Representative immunostaining of GLUT1. Scale bars, 100 μm.(N) Kaplan-Meier analyses of progression-free survival (upper) and overall survival (lower) in patients with advanced-stage ALDH-positive endometrial cancer. The patients were stratified into GLUT1-high (red lines, n = 7) and GLUT1-low (gray lines, n = 8) groups.^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

To examine whether GLUT1 mediates enhanced cell growth and stem-like property that is conferred by ALDH, we inhibited GLUT1 expression using shRNA lentiviral transfer ([Figures 7](#fig7){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}G). After inhibition of GLUT1, repression of spheroid cell growth and glucose uptake were observed ([Figures 7](#fig7){ref-type="fig"}C--7E and [S4](#mmc1){ref-type="supplementary-material"}H--S4J). In accordance, treatment with BAY876, a specific GLUT1 inhibitor, preferentially suppressed the cell viability and glucose uptake in ALDH-high cells ([Figures 7](#fig7){ref-type="fig"}F, 7G, [S4](#mmc1){ref-type="supplementary-material"}K, and S4L). Inhibition of GLUT1 also decreased the expression of stemness markers, including Nanog, and c-myc ([Figures 7](#fig7){ref-type="fig"}B, 7H, [S4](#mmc1){ref-type="supplementary-material"}G, and S4M). These data indicated that glucose uptake via GLUT1 is functionally important for the survival of ALDH-high endometrial CSCs.

Remarkably, inhibition of GLUT1 by RNAi or BAY876 sensitized spheroid cells to paclitaxel and synergistically suppressed the spheroid cell propagation *in vitro* ([Figures 7](#fig7){ref-type="fig"}I, 7J, [S4](#mmc1){ref-type="supplementary-material"}N, and S4O) and tumor propagation *in vivo* ([Figures 7](#fig7){ref-type="fig"}K and 7L), thus phenocopying the effect of combination treatment of paclitaxel and disulfiram ([Figures 4](#fig4){ref-type="fig"}F, 4H, and [S3](#mmc1){ref-type="supplementary-material"}E). These data indicate that GLUT1 mediates ALDH function to confer stem-like properties and paclitaxel resistance to the endometrial cancer spheroids.

Finally, to evaluate whether GLUT1 expression was associated with poor clinical outcome, we examined GLUT1 expression in clinical endometrial cancer tissue specimens by immunohistochemical staining ([Figure 7](#fig7){ref-type="fig"}M). We focused on advanced-stage cancer cases with high ALDH1A1 expression (n = 15), which were linked to poor prognosis ([Figure 5](#fig5){ref-type="fig"}). Kaplan-Meier survival analyses showed that high GLUT1 expression correlated with reduced survival rate ([Figure 7](#fig7){ref-type="fig"}N; p = 0.032 for progression-free survival; p = 0.04 for overall survival), suggesting that GLUT1 expression was associated with poor prognosis in advanced-stage endometrial cancer.

Discussion {#sec3}
==========

To develop novel clinical therapeutic strategies for refractory cancer, particularly for targeting CSCs, *in vitro* cultivation models can be invaluable tools. The floating spheroid culture method, which has been widely used for CSC research, retains characteristics of original tumors ([@bib17]). While short-term cultivation methods of three-dimensional cells from endometrial cancer tumor specimens ([@bib10], [@bib20]), and three-dimensional endometrial cancer cells after primary attachment cultivation in the presence of serum ([@bib7]), have been reported previously, we demonstrated, for the first time, that endometrial cancer spheroids with CSC characteristics could be stably propagated *in vitro*. Notably, we observed that spheroid cells could be preferentially established from high-grade tumors. This is advantageous for clinical application because high-grade endometrial cancer with poor prognosis is associated with clinically relevant cells with malignant traits ([@bib29]).

ALDH activity has been shown to be a specific marker of normal stem cells ([@bib47]) and various types of CSCs including endometrial cancer ([@bib9], [@bib16], [@bib21], [@bib38], [@bib49]). It is not clear whether the functional importance can be expanded for other types of cancer, although the functional importance of ALDH activity has been shown for some cancer cells ([@bib16], [@bib23]).

In this study, we demonstrated that ALDH-high endometrial cancer spheroid cells satisfied various criteria of CSCs. Functional analyses in endometrial spheroids showed that ALDH activity or ALDH1A1 expression promoted the proliferation and survival of endometrial CSCs. In addition, immunohistochemical studies of the clinical tumor showed that high levels of ALDH1A1 expression were associated with poor prognosis and advanced histological tumor grade in patients with endometrial cancer. These results suggested that ALDH1A1 expression facilitated the proliferation of endometrial CSCs, leading to a more aggressive and undifferentiated state in clinical tumors during disease progression ([@bib28]).

Resistance to current chemotherapy is one of the characteristics of CSCs, and chemotherapy preferentially selects CSC populations ([@bib30], [@bib22], [@bib12], [@bib5]). Our data obtained from *in vitro* spheroids and clinical specimens showed that paclitaxel selectively increased the proportion of ALDH-high cells, indicating that ALDH-high endometrial CSCs were resistant to paclitaxel. These observations led us to examine the synergistic effects of paclitaxel and ALDH inhibitors, and we found that the combination therapy strongly suppressed the proliferation of endometrial cancer cells. Interestingly, increased levels of ALDH activity were observed in breast and ovarian cancer cells after paclitaxel exposure ([@bib12], [@bib34]), and similar combination therapy was shown to be applicable in the treatment of taxane-resistant breast and ovarian cancer cells ([@bib18], [@bib25], [@bib51]).

It has been reported that, in many types of cancer, CSCs depend on enhanced glycolysis for their proliferation ([@bib27], [@bib24]). Our data indicate that GLUT1 is a crucial downstream effector of ALDH, thus linking ALDH activation and glycolytic pathway in endometrial CSCs. It was previously shown that GLUT1 overexpression is commonly associated with cancer metabolism ([@bib1]). In addition, GLUT1 is essential for the self-renewal and tumor-initiating capacity of glioma CSCs ([@bib42]), and GLUT inhibition and anticancer drug cooperated to suppress other types of cancer ([@bib24]). Hence, the ALDH-GLUT1 cascade may serve as a crucial pathway for the maintenance of CSCs and chemoresistance ([Figure S4](#mmc1){ref-type="supplementary-material"}P). Because spheroids presumably maintain characteristics similar to those of the original tumors, we expect that endometrial spheroids and spheroid-derived xenografts may have applications in personalized medicine in the future. To preclinically identify patients who may benefit from treatment with ALDH or GLUT inhibitors, our cultivation method may be useful for screening of clinical cases showing high levels of ALDH and hence respond to anti-ALDH or GLUT therapy in combination with taxane-derived compounds.

Experimental Procedures {#sec4}
=======================

Tumor-Derived Spheroid Culture {#sec4.1}
------------------------------

All procedures were performed using protocols approved by the Ethics Committee of Niigata University and the National Cancer Center. Informed consent was obtained from all patients. Endometrial cancer cells from tumor samples were grown on ultra-low-attachment culture dishes (Corning, NY, USA) in StemPro hESC SFM (Gibco) supplemented with 8 ng/mL basic fibroblast growth factor (Invitrogen, Carlsbad, CA) and penicillin/streptomycin (37°C, 5% CO~2~).

Animal Experiments {#sec4.2}
------------------

For cell transplantation assays in spheroid cells, the spheroids were dissociated into single cells with Accumax, suspended in 50 μL medium containing 50% Matrigel (BD Biosciences), and used for subcutaneous injection with a 27-G needle into the flanks of NOG (NOD/Shi-scid IL-2Rγnull) mice (Central Institute for Experimental Animals, Kawasaki, Japan). All mouse procedures were approved by the Animal Care and Use Committees of Niigata University and performed in accordance with institutional policies.

Lentivirus-Mediated Short Hairpin RNA Transduction {#sec4.3}
--------------------------------------------------

Lentivirus plasmid expressing ALDH1A1 short hairpin RNAs (shRNAs) (sh4, TRCN0000276460; sh5, TRCN0000276461), GLUT1 shRNAs (sh4, TRCN0000424030; sh5, TRCN0000423590), and control shRNA were purchased from Sigma. The pCMV3-ALDH1A1 plasmid (HG11388-UT) and pCMV3 control vector were purchased from Sino Biological. Preparation of virus-containing supernatants and virus infection were performed as previously described ([@bib16]). Cells infected with the viruses were selected in the presence of 2 μg/mL puromycin or 100 μg/mL hygromycin.

Western Blot Analyses {#sec4.4}
---------------------

Cells were lysed in RIPA buffer (50 mM Tris \[pH 8.0\], 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, and 1 mM EDTA) supplemented with protease inhibitors (Roche) and used for Western blot analysis, as described previously ([@bib16]), with primary antibodies ([Table S6](#mmc2){ref-type="supplementary-material"}).

Statistical Analyses {#sec4.5}
--------------------

For statistical analyses of spheroid cell experiments, Welch t tests or Student\'s t tests were performed based on the results of F tests. Differences with p values of less than 0.05 were considered significant. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. Statistical analyses of clinical samples were performed using EZR ([@bib19]). Univariate survival analysis was performed using the Kaplan-Meier method, and the significance of difference between groups was examined using log rank tests. Multivariate survival analysis was carried out using the Cox proportional hazards regression model. Hazard ratios and 95% confidence intervals were calculated with Cox\'s proportional hazards regression model. Variables with p values of less than 0.05 on univariate regression analysis were examined in multivariate regression analysis.

Additional materials and methods can be retrieved in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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